According to several studies, the KRAS mutation accounted for approximately 50%, the PTEN mutation for 35%, and the CTNNB1 mutation for 12%.5,14,15 In some patients, cancer genomic profiling tests may reveal mutations, being useful for selecting a treatment method.14,16. This evidence concerns the gene KRAS and cancer.